Paper35011990
Everolimus Reduces Cancer Incidence and Improves Patient and Graft Survival Rates after Kidney Transplantation: A Multi-Center Study.
Imamura R and 12 others. J Clin Med, 2022. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Everolimus Reduces Cancer Incidence and Improves Patient and Graft Survival Rates after Kidney Transplantation: A Multi-Center Study. Papers, record 35011990. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35011990
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Everolimus Reduces Cancer Incidence and Improves Patient and Graft Survival Rates after Kidney Transplantation: A Multi-Center Study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29100424 | Long-term allograft and patient outcomes of kidney transplant recipients with and without incident cancer - a population cohort study. | Oncotarget | 2017 | https://conductscience.org/library/papers/29100424 | PubMed |
| 2 | 20455882 | Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. | Am J Transplant | 2010 | https://conductscience.org/library/papers/20455882 | PubMed |
| 3 | 9603954 | Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. | J Biol Chem | 1998 | https://conductscience.org/library/papers/9603954 | PubMed |
| 4 | 25088685 | A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. | Am J Transplant | 2014 | https://conductscience.org/library/papers/25088685 | PubMed |
| 5 | 18256371 | Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference. | Clin J Am Soc Nephrol | 2008 | https://conductscience.org/library/papers/18256371 | PubMed |
| 6 | 23222892 | Time on dialysis and cancer risk after kidney transplantation. | Transplantation | 2013 | https://conductscience.org/library/papers/23222892 | PubMed |
| 7 | 30155929 | Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma. | Int J Cancer | 2019 | https://conductscience.org/library/papers/30155929 | PubMed |
| 8 | 19155967 | The role of mTOR inhibitors in the management of posttransplant malignancy. | Transplantation | 2009 | https://conductscience.org/library/papers/19155967 | PubMed |
| 9 | 16286900 | mTOR inhibition and its effect on cancer in transplantation. | Transplantation | 2005 | https://conductscience.org/library/papers/16286900 | PubMed |
| 10 | 15548972 | Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. | Transplantation | 2004 | https://conductscience.org/library/papers/15548972 | PubMed |
| 11 | 24684741 | Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies. | Transpl Int | 2014 | https://conductscience.org/library/papers/24684741 | PubMed |
| 12 | 15122205 | The TOR pathway: a target for cancer therapy. | Nat Rev Cancer | 2004 | https://conductscience.org/library/papers/15122205 | PubMed |
| 13 | 17538086 | Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. | N Engl J Med | 2007 | https://conductscience.org/library/papers/17538086 | PubMed |
| 14 | 27445164 | Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients. | Clin J Am Soc Nephrol | 2016 | https://conductscience.org/library/papers/27445164 | PubMed |
| 15 | 22343319 | Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression. | Cancer Lett | 2012 | https://conductscience.org/library/papers/22343319 | PubMed |
| 16 | 22420843 | Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. | Am J Transplant | 2012 | https://conductscience.org/library/papers/22420843 | PubMed |
| 17 | 20642495 | Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation? | Transpl Int | 2011 | https://conductscience.org/library/papers/20642495 | PubMed |
| 18 | 18094377 | Reduced exposure to calcineurin inhibitors in renal transplantation. | N Engl J Med | 2007 | https://conductscience.org/library/papers/18094377 | PubMed |
| 19 | 26686199 | The benefits of cancer screening in kidney transplant recipients: a single-center experience. | Cancer Med | 2016 | https://conductscience.org/library/papers/26686199 | PubMed |
| 20 | 16162203 | Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. | Am J Transplant | 2005 | https://conductscience.org/library/papers/16162203 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42970195 | Long-term outcomes of a quadruple calcineurin inhibitor-minimization regimen with everolimus introduced 3-6 months after kidney transplantation. | Clin Exp Nephrol | 2026 | https://conductscience.org/library/papers/42970195 | PubMed |
| 41583478 | Risk factors for cancer and the importance of screening in adult recipients of living-donor kidney transplant. | Front Immunol | 2025 | https://conductscience.org/library/papers/41583478 | PubMed |
| 41340872 | Astragalin: A promising herbal compound with broad anticancer potential (Review). | Oncol Lett | 2026 | https://conductscience.org/library/papers/41340872 | PubMed |
| 39589637 | Analysis of research trends and hotspots in the primary treatment of end-stage renal disease. | Int Urol Nephrol | 2025 | https://conductscience.org/library/papers/39589637 | PubMed |
| 39533221 | Sirolimus-induced pulmonary toxicity without recurrence more than 8 years after everolimus replacement in a renal transplant patient with recurrent skin SCC: a case report. | BMC Nephrol | 2024 | https://conductscience.org/library/papers/39533221 | PubMed |
| 37892805 | Difficult-to-Treat Rejections in Kidney Transplant Recipients: Our Experience with Everolimus-Based Quadruple Maintenance Therapy. | J Clin Med | 2023 | https://conductscience.org/library/papers/37892805 | PubMed |
| 35887954 | Special Issue: New Advances in Kidney Transplantation. | J Clin Med | 2022 | https://conductscience.org/library/papers/35887954 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| CXCR3 | 2833 | PubTator's text mining | https://conductscience.org/library/genes/2833 | NCBI Gene |
| CXCR4 | 7852 | PubTator's text mining | https://conductscience.org/library/genes/7852 | NCBI Gene |
| FKBP1A | 2280 | PubTator's text mining | https://conductscience.org/library/genes/2280 | NCBI Gene |
| IL2RA | 3559 | PubTator's text mining | https://conductscience.org/library/genes/3559 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| PIK3R1 | 5295 | PubTator's text mining | https://conductscience.org/library/genes/5295 | NCBI Gene |
| PTEN | 5728 | PubTator's text mining | https://conductscience.org/library/genes/5728 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35011990
GET https://conductscience.org/api/papers/v1/35011990/references?page=2